Share This

Related Topics News -

     
 Detail   |   Print    Next page > 
     
加科思一致行動人士權益變動 持股降至25.21%
2025-05-01T  
《業績》加科思全年虧損收窄至1.56億人民幣
2025-03-20T  
加科思戈來雷塞有良好安全性特徵 已向內地提交新藥上市申請
2025-01-07T  
加科思於美國展示治療骨髓纖維化藥物臨床數據
2024-12-09T  
加科思治療腫瘤突變藥物於中國完成首例患者給藥
2024-11-25T  
加科思戈來雷塞獲歐洲胰腺癌孤兒藥療法認定
2024-10-21T  
加科思:戈來雷塞和JAB-3312在體外和體內實驗均表現強大抗腫瘤作用
2024-10-09T  
加科思將於美國血液學會年會展示BET抑制劑JAB-8263臨床數據
2024-10-03T  
加科思:收到與艾力斯獨家對外許可協議首付款等1.73億人幣
2024-09-27T  
加科思自研藥物AB-23E73獲國家藥監局批准新藥臨床試驗
2024-09-26T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.